FDA Surveys Teens on 'Real Cost' of Smoking Ads Impact
Published Date: 5/13/2026
Notice
Summary
The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.
Analyzed Economic Effects
4 provisions identified: 1 benefits, 1 costs, 2 mixed.
Longitudinal Youth Survey Recruiting
FDA is extending the ExPECTT Cohort 3 study that surveys U.S. youth about tobacco. The study began in February 2023, targets youth ages 11-17 at baseline (with a supplemental social-media sample of ages 14-20), and includes a baseline plus up to eight follow-up surveys conducted about every 6-9 months; up to 14,053 youth may be surveyed at each follow-up wave.
Participant Time Burden and No Monetary Costs
FDA estimates the total respondent burden for the study extension at 59,799 hours. Individual study tasks include a youth survey of 0.50 hours (30 minutes) per response and household recruitment materials taking about 0.05 hours (9 minutes); FDA states there are no capital or operating and maintenance costs for respondents.
Parental Permission Waiver for 14+ Youth
FDA received an institutional review board waiver of parental permission for youth aged 14 and older, so parental permission is not required for those participants. Parental permission remains required for younger youth and for certain recruitment and recontact activities.
Removal of Gender Identity Questions
To comply with Executive Order 14168, FDA will not assess or examine gender or gender identity in this study. The survey includes one sexual orientation item and one sex item: 'Are you female or male?'.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
Previous / Next Documents
Previous: 2026-09447, Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in June 2026 to review and evaluate important health research grant applications. These meetings protect private info and trade secrets while deciding which projects get funding. Researchers applying for grants and the NIH community should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.
Next: 2026-09449, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; State Authorization
The Department of Education is asking to keep collecting info from states and schools without changing the current process. This affects private groups and government agencies who provide education, and they have until June 12, 2026, to share their thoughts. The paperwork won’t cost extra money but takes about 2,700 hours total each year to complete.